Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Second-line Treatment of Chemotherapy-induced Thrombocytopenia in Hematologic Malignancies
ChiCTR2500109111Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in Thrombocytopenia and chemotherapy-induced thrombocytopenia (CIT), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoint: Response Rate of Romiplostim for Injection N01. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopeniachemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2500109111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109111.